CD33 and acute myeloid leukemia: On September 01, 2017, the FDA approved the CD33-targeted monoclonal antibody gemtuzumab ozogamicin (GO) for the treatment of newly diagnosed CD33-positive AML in adults and for treatment of relapsed/refractory CD33-positive AML in adults and pediatric patients 2 years and older.